Your browser is no longer supported. Please, upgrade your browser.
Aziyo Biologics, Inc.
Index- P/E- EPS (ttm)-2.06 Insider Own8.76% Shs Outstand10.23M Perf Week-18.77%
Market Cap44.73M Forward P/E- EPS next Y-2.06 Insider Trans0.00% Shs Float6.50M Perf Month-28.87%
Income-21.10M PEG- EPS next Q-0.46 Inst Own90.80% Short Float0.14% Perf Quarter-49.52%
Sales49.00M P/S0.91 EPS this Y-112.20% Inst Trans-1.57% Short Ratio0.57 Perf Half Y-59.27%
Book/sh0.77 P/B5.51 EPS next Y11.00% ROA-29.50% Target Price14.00 Perf Year-71.39%
Cash/sh2.13 P/C1.99 EPS next 5Y- ROE-140.60% 52W Range4.58 - 18.20 Perf YTD-68.89%
Dividend- P/FCF- EPS past 5Y- ROI-31.00% 52W High-76.70% Beta-
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin44.20% 52W Low-7.42% ATR0.39
Employees176 Current Ratio1.70 Sales Q/Q-2.50% Oper. Margin-32.90% RSI (14)23.68 Volatility7.25% 5.94%
OptionableNo Debt/Eq2.78 EPS Q/Q18.90% Profit Margin-43.10% Rel Volume0.49 Prev Close4.70
ShortableYes LT Debt/Eq1.52 EarningsNov 09 AMC Payout- Avg Volume16.54K Price4.24
Recom2.00 SMA20-25.81% SMA50-29.43% SMA200-56.10% Volume8,143 Change-9.79%
Nov-02-20Initiated Truist Buy $20
Nov-02-20Initiated Piper Sandler Overweight $20
Nov-02-20Initiated Cowen Outperform $20
Nov-02-20Initiated Cantor Fitzgerald Overweight $20
Nov-15-21 04:05PM  
Nov-09-21 05:25PM  
Nov-02-21 03:02PM  
Oct-26-21 08:30AM  
Oct-25-21 04:01PM  
Sep-15-21 04:05PM  
Aug-31-21 04:05PM  
Aug-15-21 03:05AM  
Aug-09-21 04:01PM  
Jul-26-21 04:01PM  
Jun-30-21 09:34AM  
Jun-10-21 01:30AM  
Jun-07-21 08:00AM  
May-04-21 04:05PM  
Apr-28-21 04:05PM  
Apr-26-21 04:05PM  
Apr-20-21 04:05PM  
Mar-01-21 04:05PM  
Feb-18-21 04:05PM  
Feb-17-21 04:05PM  
Feb-15-21 12:00PM  
Feb-11-21 04:05PM  
Jan-28-21 04:05PM  
Jan-12-21 09:00AM  
Jan-10-21 11:58PM  
Nov-19-20 04:05PM  
Nov-17-20 04:05PM  
Nov-16-20 04:05PM  
Nov-12-20 04:05PM  
Nov-05-20 04:05PM  
Oct-08-20 03:35PM  
Oct-07-20 08:52PM  
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. The company also provides FiberCel, ViBone, and OsterGro V that are designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. In addition, it offers contract manufacturing services for various products to corporate customers. The company sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. Aziyo Biologics, Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferguson MatthewCHIEF FINANCIAL OFFICERMay 11Buy11.001,00011,0002,300May 12 06:01 PM
Ferguson MatthewCHIEF FINANCIAL OFFICERMay 10Buy11.141,30014,4821,300May 12 06:01 PM
LLOYD RONALD K.PRESIDENT AND CEOMay 07Buy11.758,565100,64323,151May 11 04:40 PM